Champions Oncology Inc (CSBR)
NASDAQHealth CareBiotechnologySnapshot 2026-10-29
$4.810.00%
Close 2026-10-30 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-10-29
Research Workspace
Put CSBR beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Biotechnology is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
The reason to own it still holds.
View ThesisRevenue growth is slowing — up about 7% over the past year and decelerating.
View GrowthMiddle-of-the-pack management execution.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationThis stock is highly volatile — it swings about 2% on a typical day and fell roughly 40% in its worst 12-month stretch.
View RiskCSBR’s data-licensing growth is the central bet, though recent financial performance remains weak. Revenue growth slowed from 12% in fiscal fourth-quarter 2026 to 8.8% in Q1 FY2027. The Q1 FY2027 call cited a data-licensing surge supporting continued revenue growth. CSBR trades at 1.1× sales versus a 9.6× peer median, and 1.2× its historical multiple. The price reflects less growth than our forecast, though depressed earnings weaken the peer comparison. Our model puts the next-quarter miss probability near 52%. Peer multiples imply a price about 88% above where it trades; our read remains intact, and this read is provisional.
Trailing returns as of 2026-10-30. CSBR is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Continue this research
Compare CSBR with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| CSBR Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 1 valuation methods, at three horizons. As of 2026-10-29. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Compare the value case
Put CSBR next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Drive continued revenue growth
Data licensing surge supports revenue growth objective.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-30. EPS is implied from price ÷ P/E. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Below average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Advances: Drive continued revenue growth
Q1 revenue growth signals strong fiscal momentum.
Advances: Drive continued revenue growth
Earnings beat supports revenue growth objective.
Advances: Achieve positive adjusted EBITDA for fiscal year
Fiscal 2027 plan aligns with achieving positive adjusted EBITDA.